Atrasentan demonstrates survival benefit in hormone-refractory prostate cancer.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000077868:Atrasentan; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D065128:Endothelin Receptor Antagonists; D006728:Hormones / Q000502:physiology; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality; D011759:Pyrrolidines; D044022:Receptor, Endothelin A; D015996:Survival Rate
D000970:Antineoplastic Agents; D065128:Endothelin Receptor Antagonists; D006728:Hormones; D011759:Pyrrolidines; D044022:Receptor, Endothelin A; D000077868:Atrasentan